Mitomycin C is produced by a strain of actinomyces, Streptomyces caespitosus. It contains three anticancer moieties, quinine, urethane, and aziridine groups. It is used to generate mitotically inactive feeder cells in cell culture systems, such as the mitotically inactive fibroblasts used in embryonic stem cell systems.
This product is an alkylating agent that specifically targets the guanine nucleoside sequence 5′-CpG-3′. It inhibits DNA synthesis by covalently reacting with DNA, forming crosslinks between complementary strands of DNA. This interaction prevents separation of complementary DNA strands, inhibiting DNA replication.
Mitomycin C has strong antitumor activity, especially against Ehrlich ascites tumor cells, and strong bactericidal action against gram-positive and gram-negative bacteria. Mitomycin c role in pluripotent stem cells research expands into the CRISPR/Cas9 revolution to permit efficient gene correction.
Additional Information
| Synonyms | MMC, Mutamycin, Ametycin, Mitocin-C |
|---|---|
| Product # | M-1108 |
| CAS # | 50-07-7 |
| Chemical Name | [(1AS,8S,8AR,8BS)-6-AMINO-8A-METHOXY-5-METHYL-4,7-DIOXO-1,1A,2,4,7,8,8A,8B-OCTAHYDROAZIRENO[2',3':3,4]PYRROLO[1,2-A]INDOL-8-YL]METHYL CARBAMATE |
| Formula | C15H18N4O5 |
| MW | 334.3 |
| Appearance | Blue-Violet Crystals |
| Purity | 98% |
| Solubility | Soluble in water (100 mg/ml at 25 °C), ethanol (50 mM), methanol (5 mg/ml), DMSO (100 mM), and DMF |
| Boiling Point | 581.8±50.0 °C at 760 mmHg |
| Storage Temp | -20°C |
| Therapeutic Area | Oncological Disorders |
| Use | A DNA crosslinking agent that inhibits DNA synthesis and induces apoptosis in a variety of cells use in cancer |
Additional Information
| Merck Index | 13.6236[p.2001 |
|---|---|
| MDL Number | MFCD00078109 |
| ChemACX | X1004059-0 |
| InChI | InChI=1S/C15H18N4O5/c1-5-9(16)12(21)8-6(4-24-14(17)22)15(23-2)13-7(18-13)3-19(15)10(8)11(5)20/h6-7,13,18H,3-4,16H2,1-2H3,(H2,17,22)/t6-,7+,13+,15-/m1/s1 |
| SMILES | CC1=C(C(=O)C2=C(C1=O)N3C[C@H]4[C@@H]([C@@]3([C@@H]2COC(=O)N)OC)N4)N |
